DDInter126 DDInter1082
Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to As
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Asparaginase Erwinia chrysanthemi {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acitretin
Asparaginase Erwinia chrysanthemi {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Blinatumomab
Asparaginase Erwinia chrysanthemi {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Acitretin
Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Asparaginase Erwinia chrysanthemi may lead to a major life threatening interaction when taken with Teriflunomide